GlassScriptPhysician profile
Vincent R Demarco
NPI 1942649538
$9,960.16
in general payments reported to CMS, 2019-2025
53 companies · $1,030 in 2025
The $1,030 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,273 · 2020: $781 · 2021: $1,009 · 2022: $522 · 2023: $828 · 2024: $1,515 · 2025: $1,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,373.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valeritas, INC. | $3,726.40 | 2019 | |
| Abbvie INC. | $797.54 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $630.20 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $464.71 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $456.74 | 2019-2024 | Synjardy, Jardiance, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $456.54 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $361.78 | 2019-2025 | |
| Amgen INC. | $341.45 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $215.48 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $185.27 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $184.35 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $141.35 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $137.07 | 2019-2025 | Ajovy |
| Corcept Therapeutics | $131.72 | 2023-2024 | Korlym |
| Otsuka America Pharmaceutical, INC. | $125.29 | 2023-2025 | Rexulti |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Demarco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.